Cancer Didn't Stop for COVID-19. Neither Can We.
An Interactive Roundtable on the Impacts of the Pandemic for Radiation Oncology
Thank you for your interest in this webinar. If you missed the live event, we invite you to watch the replay:
A May 2020 editorial in The Lancet makes the important point that the COVID-19 pandemic has resulted in cancer care being "deprioritized, delayed", and in some places, discontinued. Cancer patients "are facing disruption for all but the most urgent procedures."
But in truth, clinical teams have scrambled to find ways of continuing to serve their cancer patients, despite the challenges. This panel discussion will cover perspectives on how practice patterns have had to change suddenly due to the impact of COVID-19 on cancer care. Speakers will offer their views about the long-term impacts in radiation oncology, covering:
- Clinical practice pattern changes that had to be implemented
- Impact on case mix and presentation stage
- Changes in workload and departmental strategies
- Coping strategies for individuals and teams
- Implications for resource allocation
Prof. Dr. Ferran Guedea Edo, MD, Ph.D.,
Director of the Department of Radiation Oncology at the Catalan Institute of Oncology in Barcelona, Spain.
Dr. Guedea Edo is professor of Radiation Oncology at the Universitat de Barcelona (UB). He is one of the leading experts in radiotherapy of prostate, new technologies and brachytherapy. He has been past president of the Spanish Society of Radiation Oncology and past member of ESTRO Board. Dr. Guedea has been recognized by awards such as the Gold Medal of the SFRO (Société Française de Radiothérapie Oncologique) and the Gold medal of ALATRO (Asociación Latinoamericana de terapia Radiante). He is co-editor of Reports of Practical Oncology and Radiotherapy, and member on the editorial committee for several international Journals.
CEO of the ICON Group, and Executive Director of its Board of Directors
ICON Group is Australia’s largest dedicated provider of cancer care with a growing reach into Asia and New Zealand. Under his leadership, Icon has grown from 12 to 30 cancer centres. Mark has also overseen robust international expansion into New Zealand, Singapore, the wider South East Asian region, China and Hong Kong. In 2018, Mark was appointed Director on the inaugural City Cancer Challenge Board. A frequent international key note speaker, Mark is also a Fellow of both the Australian Society of Medical Imaging and Radiation Therapy (ASMIRT) and the Australian Institute of Managers and Leaders (IML).
Assos. Prof. Dr. Satoaki Nakamura, MD, Ph.D.
Division Head of the Radiation Oncology Department and Associate Professor at Kansai Medical University in Osaka, Japan.
Dr. Nakamura’s clinical interests include the treatment of head & neck, pancreatic, and bile duct cancer; treatment modalities like IMRT and SBRT, and radiation biology. He has been the leader of JASTRO COVID-19 working group, showing leadership for the establishment of prevention measures in Japan during this outbreak.
Prof. Dr. Ricky Sharma, MD, Ph.D.
Vice President of Clinical Affairs at Varian
A pioneer in internal radiotherapy and chemotherapy treatments for patients with liver metastases, Dr. Sharma is an international authority on the translation of radiobiology from the laboratory to the clinic and on the multi-modality treatment of cancer with precision radiotherapy. He has served as the global chief investigator in 15 phase I, II or III clinical trials in the fields of radiation, medical, and interventional oncology. Prior to joining Varian, Dr. Sharma was the Chair of Radiation Oncology at University College London, UK, where he continues as an honorary clinical professor.